硫辛酸治疗缓解期多发性硬化疗效观察

Effect of lipoic acid on paracmastic multiple sclerosis

目的探讨硫辛酸治疗缓解期多发性硬化(MS)的临床效果。方法 70例缓解期MS患者分为观察组40例和对照组30例,观察组患者给予硫辛酸胶囊0.2 g,口服,每日3次;对照组患者给予补肾益髓胶囊5粒,口服,每日3次;2组均1个月为1个疗程,持续治疗3个疗程。分别于治疗前及治疗1、3个月应用扩展残疾状态量表(EDSS)对患者日常生活能力进行评分。结果治疗前2组患者EDSS评分比较差异无统计学意义(P>0.05);2组患者治疗1、3个月时EDSS评分均显著低于治疗前(P<0.05),2组患者治疗3个月时EDSS评分均显著低于治疗1个月时(P<0.05);治疗1、3个月时,观察组患者EDSS评分显著低于对照组(P<0.05)。对照组和观察组患者治疗总有效率分别为70.0%(21/30)和90.0%(36/40),观察组患者治疗总有效率高于对照组(P<0.05)。2组患者均未发生明显不良反应。结论硫辛酸可以显著改善缓解期MS患者的神经功能,提高患者生活能力,且无明显不良反应。

Objective To investigate the clinical effect of lipoic acid on paracmastic multiple sclerosis（ MS）. Methods Seventy patients with paracmastic MS were divided into observation group（ n = 40） and control group（ n = 30）. The patients in observation group were treated with thioctic acid capsule 0. 2 g by oral,three times a day. The patients in control group were treated with Bushen Yisui capsule by oral,5 capsules each time,three times a day. One month was one course of treatment,and all the patients in the two groups were treated for three courses. The activity of daily living of the patients was evaluated by expanded disability status scale（ EDSS） before treatment and 1 month,3 months after treatment. Results There was no significant difference in EDSS score between the two groups before treatment（ P〉0. 05）. The EDSS scores after treatment of 1 month and 3 months were significantly lower than those before treatment in the two groups（ P〈0. 05）. The EDSS scores after treatment of 3 months were significantly lower than those after treatment of 1 month in the two groups（ P〈0. 05）. The EDSS scores in observation group were significantly lower than those in control group after treatment of 1 month and 3 months（ P〈0. 05）.The total effective rate in control group and observation group was 70. 0%（ 21 /30） and 90. 0%（ 36 /40） respectively,which in observation group was higher than that in control group（ P〈0. 05）. There was no significant adverse reaction in the two groups. Conclusion Thioctic acid can significantly improve the neurological function and living ability of patients with paracmastic MS,and without obvious adverse reactions.